Zhengye Biotechnology (NASDAQ:ZYBT) Trading Up 2.8% – Still a Buy?

Shares of Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) rose 2.8% during mid-day trading on Thursday . The company traded as high as $1.84 and last traded at $1.84. Approximately 17,284 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 25,481 shares. The stock had previously closed at $1.79.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Zhengye Biotechnology in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Zhengye Biotechnology Trading Up 0.5%

The stock’s fifty day moving average price is $2.23 and its 200-day moving average price is $5.09.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZYBT. Citadel Advisors LLC bought a new position in Zhengye Biotechnology in the 3rd quarter worth $31,000. Millennium Management LLC acquired a new position in shares of Zhengye Biotechnology in the third quarter valued at $38,000. WINTON GROUP Ltd bought a new position in shares of Zhengye Biotechnology during the 3rd quarter worth about $56,000. Geode Capital Management LLC bought a new stake in shares of Zhengye Biotechnology in the 2nd quarter valued at approximately $174,000. Finally, Invesco Ltd. bought a new stake in Zhengye Biotechnology in the second quarter valued at $220,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.